Seqirus USA Inc.

Seqirus USA Inc., a foreign-owned biotechnology manufacturer headquartered in Summit, New Jersey, manufactures and delivers influenza vaccines to federal agencies as a prime contractor across nearly two thousand awards carrying over $7.27 billion in combined potential value, competing without set-aside designations in a full-and-open posture across civilian health and defense agencies.

The company's federal capability footprint centers on seasonal influenza vaccine procurement and supply. Seqirus manufactures quadrivalent vaccines, multi-dose vials, pre-filled syringes, and high-dose formulations for pediatric, adult, and elderly populations. Recent concrete work includes a $30.9 million single-award indefinite delivery contract with the VA National Acquisition Center for 2026-2027 flu vaccines serving Veterans Integrated Service Networks, federal correctional institutions, and federal medical centers; a $168.1 million multiple-award CDC contract for pediatric influenza vaccines awarded December 2025; and an $82.7 million multiple-award CDC contract for adult influenza vaccines also awarded December 2025. At the transaction level, Seqirus placed delivery orders for individual facilities: a $2.68 million order from the Indian Health Service on August 15, 2026, for six-months-and-older populations; a $10.7 million Defense Logistics Agency order on February 18, 2026; and routine small orders to federal correctional facilities (ranging from under $500 to several thousand dollars) for inmate and staff flu shots under its Bureau of Prisons contract vehicle.

Customer concentration is split between volume-driven and value-driven tiers. By award count, the top five customers account for 25 percent of awards, led by VA Veterans Integrated Service Network 21 (149 awards, $12.9 million), Defense Logistics Agency Troop Support Medical (114 awards, $563.3 million), and VA VISN 20, VISN 6, and VISN 5 (73, 71, and 70 awards respectively, $11 million, $10.5 million, and $9.7 million combined). By potential value, the distribution is heavily skewed: the Centers for Disease Control and Prevention Pittsburgh accounts for 26 awards but $3.37 billion combined potential value (46 percent of the entire portfolio), while Defense Logistics Agency carries the second-largest share at $563.3 million across 114 orders. This divergence reflects Seqirus's role as both a large-dollar supplier to CDC's national vaccine stockpiling and distribution apparatus and a routine small-order supplier to individual federal health facilities.

Seqirus holds positions on multiple named indefinite delivery vehicles. The company maintains the largest volume of task orders under five VA IDCs: VA797P17C0018 (191 orders, $12.3 million), VA797P18C0011 (179 orders, $15.4 million), VA797P16C0026 (168 orders, $6.2 million), VA797P13C0042 (165 orders, $9.6 million), and VA797P14C0006 (158 orders, $8.9 million). These are routine federal correctional and veteran medical facility vaccine procurement vehicles through which individual facilities issue small delivery orders. The company also holds active CDC multiple-award contracts, the Defense Logistics Agency Medical Supply Chain single-award IDC ($36.1 million for 2024-2025), a Veterans Integrated Service Network 12 Federal Supply Schedule contract running through August 2029, and single-award VA National Acquisition Center contracts for successive flu seasons ($51.6 million for 2025-2026, $30.9 million for 2026-2027).

Activity has been volatile year-over-year, with 154 awards in 2022, then dropping to 19 in 2023 and 20 in 2024 before rising to 105 in 2025 and 48 through mid-October 2026. This volatility reflects the seasonal and award-cycle nature of federal influenza vaccine procurement: large CDC and DLA contracts are periodically recompeted, and small facility orders cluster around flu season (September through April). Forty awards with a combined potential value of $15.9 million face ultimate completion within the next twenty-four months and thus represent recompete or task-order-renewal exposure for Seqirus and competitive opportunity for challengers.

Seqirus operates entirely as a prime contractor—the source data carries no subcontract awards. The company's footprint is concentrated in pharmaceutical manufacturing (NAICS 325412) and biological product manufacturing (102 awards), with primary PSC coding under Drugs and Biologicals (1,695 awards) and Medical and Surgical Instruments (97 awards). All awards carry no set-aside designation, confirming competitive (rather than set-aside-restricted) positioning.

The company's manufacturing footprint is centered in Summit, New Jersey, with secondary facilities in Swiftwater, Pennsylvania, and distribution activity reported from King of Prussia, Pennsylvania. Seqirus has maintained registered federal contractor status since 2008 and draws its federal customer base from 131 distinct federal agencies and sub-offices, with the heaviest concentration among VA networks, Defense Logistics Agency, CDC, Indian Health Service, Bureau of Prisons, and smaller federal medical centers and correctional facilities.